Patrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)
0
Today Patrys announced new data from a successful preclinical study highlighting the potential for using our deoxymab antibodies as targeting…
Bioshares | August 2021
Patrys has been featured in the latest edition of investor newsletter Bioshares. Bioshares has previously focused on the unmet needs…
Patrys FY21 Annual Report
Patrys has today released its Annual Report for the 2020-2021 Financial Year (FY21). Highlights include: 2020 Expansion of deoxymab portfolio…
QUARTERLY ACTIVITIES REPORT & 4C
Patrys has today released its Quarterly Activities Report and 4C for the quarter ended 30 June 2021. Our R&D program…
PAT-DX1 Significantly Improves Survival in Animal Model of Pancreatic Cancer
New preclinical data from the Garvan Institute of Medical Research has shown that Patrys’ deoxymab antibody PAT-DX1 is able to…
New data shows PAT-DX3 able to cross the blood brain barrier
In an exciting development, Patrys today announced new data confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross…
Bioshares | June 2021
Patrys has been featured in the latest edition (Edition 896) of investor newsletter Bioshares. The article highlights our Company’s strong…
Patrys in The Australian
Patrys appears on page 7 of The Australian today as part of a story secured with the newspaper’s Health Editor,…
New Data | PAT-DX1
Patrys is pleased to announce the publication of new data in the highly-regarded Journal of Clinical Investigation – Insight, demonstrating…
Newsletter | June 2021
Patrys is pleased to share its latest Newsletter, published June 2021. Key highlights: Letter from our CEO Media and analyst…